Shire to Resolve Federal Investigation and Pay $57.5 Million - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Shire to Resolve Federal Investigation and Pay $57.5 Million


ePT--the Electronic Newsletter of Pharmaceutical Technology

Shire announced that it has reached an agreement in principle with the US government to resolve the previously disclosed civil investigation into its sales and marketing practices in the US relating to the company’s attention deficit hyperactivity disorder (ADHD) drugs, Adderall XR and Vyvanse as well as the ADHD patch Daytrana. The agreement also addresses sales and marketing practices relating to Lialda and Pentasa (both for the treatment of ulcerative colitis), pursuant to a subsequent voluntary disclosure made by Shire.

Shire has provided full cooperation to the US government throughout the process of reaching this agreement. The company will pay out $57.5 million from its fourth quarter earnings in 2012 to cover costs of the agreement and interest. The agreement is subject to change until the matter has been fully resolved. Shire and the US government are in discussions on establishing a final resolution to the investigation.

The investigation, led by the US attorney’s office for the Eastern District of Pennsylvania, was disclosed by Shire in 2009 when the company was asked for documents relating to the sales and marketing of Adderall XR, Vyvanse and Daytrana.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here